The insulin pens (diabetes care devices) market in India is expected to reach around US$400m in 2025, driven by the increasing prevalence of diabetes and the innovation of new products such as Roche’s ACCU-FINE pen needles for virtually painless insulin delivery, forecasts GlobalData, a leading data, and analytics company.

India has the second-largest number of adults with diabetes globally, after China. This is due to the increasing aging population, urbanization, and sedentary lifestyle leading to less physical activity, obesity, and weight gain.

GlobalData’s report, ‘Insulin Pens Market Size (Value, Volume, ASP) by Segments, Share, Trend and SWOT Analysis, Regulatory and Reimbursement Landscape, Procedures, and Forecast, 2015-2030’, reveals that Novo Nordisk, Eli Lilly, and Sanofi were the major players in India, accounting for about 80% of the market in 2021.

Shweta Yadav, Medical Devices Analyst at GlobalData, comments: “Recently, Roche Diabetes Care India launched ACCU-FINE insulin pen needles that enable easier insertion and rapid insulin flow. Focus on developing such innovative products will eventually lead to timely insulin delivery, which is crucial for the successful management of diabetes.”

In addition, to focus on new product innovations, companies such as Novo Nordisk, Sanofi, and Roche are offering support to diabetes patients through various digital diabetes care programs in India. These programs aim to provide tailored guidance on disease and lifestyle management, usage of insulin pens, while maintaining privacy, regulatory, and quality requirements.

Yadav concludes: “New product launches and technological advancements are expected to further drive the insulin pens market, making India emerge as one of the dominant markets in the Asia-Pacific region.”